Evidence map›Paper›PMID 37580891›Full record

ArticlePediatric blood & cancer2023

Tyrosine kinase inhibitor therapy in pediatric sarcoma: Prognostic implications of pulmonary metastatic cavitation.

Wipawee Morakote, Lisa C Adams, Shakthi K Ramasamy, Sheri L Spunt, Lucia Baratto, Tie Liang, Heike E Daldrup-Link

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Wipawee MorakoteDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, California, USA.
Lisa C AdamsDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, California, USA.
Shakthi K RamasamyDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, California, USA.
Sheri L SpuntDepartment of Pediatrics, Division of Hematology and Oncology, Stanford University, Stanford, California, USA.ORCID 0000-0002-1669-2676
Lucia BarattoDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, California, USA.
Tie LiangDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, California, USA.
Heike E Daldrup-LinkDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, California, USA.
Stanford University · USStanford Medicine · USChiang Mai University · TH

Funding

Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric PatientsR01CA269231 · NCI · STANFORD UNIVERSITY · PI Heike Elizabeth Daldrup-Link · 2022 to 2026
$3.5M
NCI NIH HHS R01 CA269231
6 · The paper itself

Abstract

purposesThis study aims to ascertain the prevalence of cavitations in pulmonary metastases among pediatric and young adult patients with sarcoma undergoing tyrosine kinase inhibitor (TKI) therapy, and assess whether cavitation can predict clinical response and survival outcomes.

methodsIn a single-center retrospective analysis, we examined chest computed tomography (CT) scans of 17 patients (median age 16 years; age range: 4-25 years) with histopathologically confirmed bone (n = 10) or soft tissue (n = 7) sarcoma who underwent TKI treatment for lung metastases. The interval between TKI initiation and the onset of lung nodule cavitation and tumor regrowth were assessed. The combination of all imaging studies and clinical data served as the reference standard for clinical responses. Progression-free survival (PFS) was compared between patients with cavitating and solid nodules using Kaplan-Meier survival analysis and log-rank test.

resultsFive out of 17 patients (29%) exhibited cavitation of pulmonary nodules during TKI therapy. The median time from TKI initiation to the first observed cavitation was 79 days (range: 46-261 days). At the time of cavitation, all patients demonstrated stable disease. When the cavities began to fill with solid tumor, 60% (3/5) of patients exhibited progression in other pulmonary nodules. The median PFS for patients with cavitated pulmonary nodules after TKI treatment (6.7 months) was significantly longer compared to patients without cavitated nodules (3.8 months; log-rank p-value = .03).

conclusionsCavitation of metastatic pulmonary nodules in sarcoma patients undergoing TKI treatment is indicative of non-progressive disease, and significantly correlates with PFS.

Indexed as

Lung NeoplasmsSarcomaTyrosine Kinase InhibitorsAdolescentAdultChildChild, PreschoolHumansPrognosisRetrospective StudiesYoung AdultTyrosine Kinase Inhibitorscavitycomputed tomographypulmonary metastasisSarcomatreatment monitoringtyrosine kinase inhibitor

Identifiers

PMID37580891
PMCPMC10947454
OpenAlexW4385827614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.